Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €87.60 EUR
Change Today -1.44 / -1.62%
Volume 1.5K
As of 7:00 AM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi-new (SANNV) Snapshot

Open
€87.60
Previous Close
€89.04
Day High
€87.60
Day Low
€87.60
52 Week High
03/24/15 - €91.50
52 Week Low
01/6/15 - €70.35
Market Cap
418.2M
Average Volume 10 Days
174.1K
EPS TTM
--
Shares Outstanding
4.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANOFI-NEW (SANNV)

sanofi-new (SANNV) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi-new (SANNV) Top Compensated Officers

Chairman, Interim Chief Executive Officer, Ch...
Total Annual Compensation: €700.0K
Compensation as of Fiscal Year 2014.

sanofi-new (SANNV) Key Developments

Evotec AG and Sanofi Sign Definitive Agreement for Major Multi-Multi-Component Strategic Alliance

Evotec AG announced the signing of a definitive agreement for a major multi-component strategic alliance over the next five years with Sanofi. The transaction is expected to close on 31 March 2015. The signing successfully concludes the exclusive negotiations for a major multi-component strategic collaboration between the two companies entered and announced on 02 December 2014. The definitive agreement defines the conditions under which Evotec and Sanofi intend to jointly progress a portfolio of primarily oncology related projects, including five advanced, pre-clinical projects and further discovery-stage assets, to IND (Investigational New Drug) status or other value inflection points before partnering them. The collaboration will result in a minimum guaranteed commitment from Sanofi to Evotec of EUR 250 million over the next five years, including more than EUR 40 million upfront cash payment.

Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(R) (lixisenatide)

Sanofi announced top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety. ELIXA full results will be presented on June 8, 2015, at the American Diabetes Association 75th Scientific Sessions in Boston by the ELIXA steering committee. The results will also be included in the U.S. New Drug Application of lixisenatide, which is on track to be resubmitted to the U.S. Food and Drug Administration in the third-quarter of 2015.

Sanofi and Regeneron Pharmaceuticals, Inc. Announce Results of a Phase 3 Trial of Praluent

Sanofi and Regeneron Pharmaceuticals, Inc. announced that 18-month (78-week) results of a Phase 3 trial of Praluent(TM) (alirocumab), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol (LDL-C or 'bad' cholesterol) by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks. ODYSSEY LONG TERM evaluated Praluent 150 mg (n=1,553) every two weeks compared to placebo (n=788) in patients who were at high cardiovascular (CV) risk and who were receiving maximally-tolerated statin therapy with or without other lipid-lowering treatment. The trial included patients with heterozygous familial hypercholesterolemia (HeFH) (n=276 Praluent, n=139 placebo). Patients received 78 weeks of treatment followed by an eight-week safety assessment. Patients self-administered a subcutaneous injection every two weeks via a pre-filled syringe.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANNV:FP €87.60 EUR -1.44

SANNV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $300.63 USD -8.50
Amgen Inc $160.62 USD -5.39
Bayer AG €137.20 EUR -2.56
Gilead Sciences Inc $99.86 USD -1.55
Medtronic PLC $77.60 USD -1.12
View Industry Companies
 

Industry Analysis

SANNV

Industry Average

Valuation SANNV Industry Range
Price/Earnings 25.8x
Price/Sales 3.3x
Price/Book 2.0x
Price/Cash Flow 16.3x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-NEW, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.